The Publisher regrets that this article is an accidental duplication of an article that has already been published, http://dx.doi.org/10.1016/j.eururo.2017.05.023. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2017.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostate artery embolization as an effective treatment for clinically significant prostate cancer‑related hemorrhage: A case report.
Exp Ther Med
February 2025
Department of Urology, Konstantopouleio-Patision General Hospital of Nea Ionia, 14233 Nea Ionia, Greece.
A 79-year old Caucasian male with metastatic hormone refractory prostate cancer and bilateral nephrostomy was admitted to the emergency department due to 4-day bloody urethral discharge, weakness and dizziness. The patient was treated with the luteinizing hormone-releasing hormone-antagonist and abiraterone acetate plus prednisone, dabigatran 150 mg bid (for atrial fibrillation and coronary heart disease) and 5-aminosalicylic acid for the management of mild ulcerative colitis. Imaging revealed bladder overdistention and blood analysis low levels of hematocrit (HCT) and hemoglobin (HGB) (HCT, 22%; HGB, 7.
View Article and Find Full Text PDFHigh Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
J Clin Oncol
December 2024
Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Purpose: Men on active surveillance (AS) for prostate cancer are extremely interested in dietary changes or supplements to prevent progression of their disease. We sought to determine whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules (D + FO) decreases proliferation (Ki-67) in prostate biopsies in men with prostate cancer on AS over a 1-year time period.
Methods: In this phase II, prospective randomized trial, men (N = 100) with grade group 1 or 2 prostate cancer who elected AS were randomly assigned to the D + FO or a control group.
Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight.
Bioorg Chem
January 2025
Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru 560107, Karnataka, India.
Article Synopsis
- The phosphatidylinositol-3 kinase (PI3K) pathway is crucial in various cancers, making it an attractive target for cancer therapies due to its role in cell survival and metastasis.
- Mutations or overexpression in PI3K genes (PIK3CA, PIK3CB, PIK3CD, PIK3CG) lead to treatment failures, prompting ongoing clinical trials of PI3K inhibitors to combat drug resistance.
- Many PI3K inhibitors have faced withdrawal due to safety concerns, but research continues on promising compounds with unique scaffolds to improve therapy efficacy and safety.
The Possible Role of Progesterone Receptors in Prostate Cancer Incidences in the Iraqi Population.
Front Biosci (Schol Ed)
September 2024
Department of Environmental Biotechnology, Al-Nahrain University, Biotechnology Research Center, 64074 Baghdad, Iraq.
Background: Prostate cancer (PCa) is one of the leading diseases causing mortality. It comes in the third rank of common cancer types. It is considered extremely a complicated cancer type since it occurs in highly steroid-responsive and dependent tissues.
View Article and Find Full Text PDFSevere neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient.
J Oncol Pharm Pract
October 2024
Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Introduction: Abiraterone and enzalutamide are two androgen receptor pathway inhibitors approved, among others, for the treatment of metastatic castration-resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based regimen. Although hematological effects, especially neutropenia, are one of the main complications of other oral antineoplastic drugs, these adverse effects are infrequent in the case of androgen receptor pathway inhibitors.
Case Report: We report the case of a patient diagnosed with metastatic castration-resistant prostate cancer who discontinued an androgen receptor pathway inhibitor due to drug-related grade 4 neutropenia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!